Spinal Cord Injury – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Spinal Cord Injury – Pipeline Review, H1 2018’, provides an overview of the Spinal Cord Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury

– The report reviews pipeline therapeutics for Spinal Cord Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Spinal Cord Injury therapeutics and enlists all their major and minor projects

– The report assesses Spinal Cord Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Spinal Cord Injury

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Acorda Therapeutics Inc

Asterias Biotherapeutics Inc

Athersys Inc

BioArctic AB

BioAxone BioSciences Inc

Biogen Inc

CSL Ltd

CSPC Pharmaceutical Group Limited

Genervon Biopharmaceuticals LLC

Hemostemix Inc

Histocell SL

K-Stemcell Co Ltd

Kadimastem Ltd

Kringle Pharma Inc

MandalMed Inc

Mapreg SAS

Neuralstem Inc

Neuronax SAS

New World Laboratories Inc

Pharmicell Co Ltd

PixarBio Corp

RDD Pharma Ltd

RespireRx Pharmaceuticals Inc

SanBio Inc

Spectrum Pharmaceuticals Inc

Stemedica Cell Technologies Inc

Sumitomo Dainippon Pharma Co Ltd

TissueGene Inc

Tumorend LLC

Vertex Pharmaceuticals Inc

Vicore Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Spinal Cord Injury Overview 6

Spinal Cord Injury Therapeutics Development 7

Spinal Cord Injury Therapeutics Assessment 17

Spinal Cord Injury Companies Involved in Therapeutics Development 27

Spinal Cord Injury Drug Profiles 41

Spinal Cord Injury Dormant Projects 172

Spinal Cord Injury Discontinued Products 177

Spinal Cord Injury Product Development Milestones 178

Appendix 189

List of Tables

List of Tables

Number of Products under Development for Spinal Cord Injury, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Spinal Cord Injury Pipeline by AbbVie Inc, H1 2018

Spinal Cord Injury Pipeline by Acorda Therapeutics Inc, H1 2018

Spinal Cord Injury Pipeline by Asterias Biotherapeutics Inc, H1 2018

Spinal Cord Injury Pipeline by Athersys Inc, H1 2018

Spinal Cord Injury Pipeline by BioArctic AB, H1 2018

Spinal Cord Injury Pipeline by BioAxone BioSciences Inc, H1 2018

Spinal Cord Injury Pipeline by Biogen Inc, H1 2018

Spinal Cord Injury Pipeline by CSL Ltd, H1 2018

Spinal Cord Injury Pipeline by CSPC Pharmaceutical Group Limited, H1 2018

Spinal Cord Injury Pipeline by Genervon Biopharmaceuticals LLC, H1 2018

Spinal Cord Injury Pipeline by Hemostemix Inc, H1 2018

Spinal Cord Injury Pipeline by Histocell SL, H1 2018

Spinal Cord Injury Pipeline by K-Stemcell Co Ltd, H1 2018

Spinal Cord Injury Pipeline by Kadimastem Ltd, H1 2018

Spinal Cord Injury Pipeline by Kringle Pharma Inc, H1 2018

Spinal Cord Injury Pipeline by MandalMed Inc, H1 2018

Spinal Cord Injury Pipeline by Mapreg SAS, H1 2018

Spinal Cord Injury Pipeline by Neuralstem Inc, H1 2018

Spinal Cord Injury Pipeline by Neuronax SAS, H1 2018

Spinal Cord Injury Pipeline by New World Laboratories Inc, H1 2018

Spinal Cord Injury Pipeline by Pharmicell Co Ltd, H1 2018

Spinal Cord Injury Pipeline by PixarBio Corp, H1 2018

Spinal Cord Injury Pipeline by RDD Pharma Ltd, H1 2018

Spinal Cord Injury Pipeline by RespireRx Pharmaceuticals Inc, H1 2018

Spinal Cord Injury Pipeline by SanBio Inc, H1 2018

Spinal Cord Injury Pipeline by Spectrum Pharmaceuticals Inc, H1 2018

Spinal Cord Injury Pipeline by Stemedica Cell Technologies Inc, H1 2018

Spinal Cord Injury Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Spinal Cord Injury Pipeline by TissueGene Inc, H1 2018

Spinal Cord Injury Pipeline by Tumorend LLC, H1 2018

Spinal Cord Injury Pipeline by Vertex Pharmaceuticals Inc, H1 2018

Spinal Cord Injury Pipeline by Vicore Pharma AB, H1 2018

Spinal Cord Injury Dormant Projects, H1 2018

Spinal Cord Injury Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Spinal Cord Injury, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports